Literature DB >> 12559176

Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels.

Dennis Hallahan1, Ling Geng, Shimian Qu, Christopher Scarfone, Todd Giorgio, Edwin Donnelly, Xiang Gao, Jeff Clanton.   

Abstract

The objective of this study was to target drug delivery to radiation-induced neoantigens, which include activated receptors within the tumor vasculature. These responses include posttranslational changes in pre-existing proteins, which can be discovered by phage-displayed peptide libraries administered to mice bearing irradiated tumors. Phage-displayed peptides recovered from irradiated tumors included the amino acid sequence RGDGSSV. This peptide binds to integrins within the tumor microvasculature. Immunohistochemical staining of irradiated tumors showed accumulation of fibrinogen receptor alpha(2b)beta(3) integrin. We studied tumor targeting efficiency of ligands to radiation-induced alpha(2b)beta(3). Radiopharmaceuticals were localized to irradiated tumors by use of alpha(2b)beta(3) ligands conjugated to nanoparticles and liposomes. Fibrinogen-conjugated nanoparticles bind to the radiation-activated receptor, obliterate tumor blood flow, and significantly increase regression and growth delay in irradiated tumors. Radiation-guided drug delivery to tumor blood vessels is a novel paradigm for targeted drug delivery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559176     DOI: 10.1016/s1535-6108(02)00238-6

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  36 in total

1.  Phage display peptide probes for imaging early response to bevacizumab treatment.

Authors:  Qizhen Cao; Shuanglong Liu; Gang Niu; Kai Chen; Yongjun Yan; Zhaofei Liu; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-16       Impact factor: 3.520

2.  Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.

Authors:  Amanda Lowery; Halina Onishko; Dennis E Hallahan; Zhaozhong Han
Journal:  J Control Release       Date:  2010-11-12       Impact factor: 9.776

Review 3.  Smart nanosystems: Bio-inspired technologies that interact with the host environment.

Authors:  Ester J Kwon; Justin H Lo; Sangeeta N Bhatia
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

Review 4.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

5.  Nanoparticle imaging of integrins on tumor cells.

Authors:  Xavier Montet; Karin Montet-Abou; Fred Reynolds; Ralph Weissleder; Lee Josephson
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

Review 6.  Prospects of nano-material in breast cancer management.

Authors:  A K Singh; A Pandey; M Tewari; R Kumar; A Sharma; H P Pandey; H S Shukla
Journal:  Pathol Oncol Res       Date:  2013-02-23       Impact factor: 3.201

Review 7.  High-Throughput Approaches to the Development of Molecular Imaging Agents.

Authors:  Lina Y Hu; Kimberly A Kelly; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

8.  Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.

Authors:  Ralph J Passarella; Daniel E Spratt; Alice E van der Ende; John G Phillips; Hongmei Wu; Vasanth Sathiyakumar; Li Zhou; Dennis E Hallahan; Eva Harth; Roberto Diaz
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

Review 9.  Nanotechnology in radiation oncology.

Authors:  Andrew Z Wang; Joel E Tepper
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

10.  Phage-display-guided nanocarrier targeting to atheroprone vasculature.

Authors:  Lucas H Hofmeister; Sue Hyun Lee; Allison E Norlander; Kim Ramil C Montaniel; Wei Chen; David G Harrison; Hak-Joon Sung
Journal:  ACS Nano       Date:  2015-03-23       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.